Speciality Medicines Limited (BOM:544738)

Speciality Medicines Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Revenue	582.71	275.25	232.41	404.44
Other Revenue	-	-	-0	-
Revenue	582.71	275.25	232.41	404.44
Revenue Growth (YoY)	111.71%	18.43%	-42.54%	-
Cost of Revenue	421.91	182.09	163.01	350.57
Gross Profit	160.81	93.16	69.4	53.87
Selling, General & Admin	28.97	22.66	33.55	14.47
Other Operating Expenses	40.31	17.9	-0.24	16.65
Operating Expenses	71.26	42.87	36.26	32.24
Operating Income	89.55	50.29	33.14	21.64
Interest Expense	-3.58	-6.05	-3.42	-0.21
Interest & Investment Income	0	-	-	0.01
Currency Exchange Gain (Loss)	2.07	1.32	-	-
Other Non Operating Income (Expenses)	-1.15	-5.35	-0.13	-0.05
Pretax Income	86.9	40.22	29.6	21.39
Income Tax Expense	14.94	-0.3	7.59	6.59
Net Income	71.96	40.51	22.01	14.79
Net Income to Common	71.96	40.51	22.01	14.79
Net Income Growth	77.62%	84.08%	48.77%	-
Shares Outstanding (Basic)	6	5	4	3
Shares Outstanding (Diluted)	6	5	4	3
Shares Change (YoY)	25.78%	42.99%	17.75%	-
EPS (Basic)	11.18	7.92	6.15	4.87
EPS (Diluted)	11.18	7.92	6.15	4.87
EPS Growth	41.21%	28.74%	26.34%	-
Free Cash Flow	-70.39	-48.25	-37.69	-12.87
Free Cash Flow Per Share	-10.94	-9.43	-10.53	-4.23
Gross Margin	27.60%	33.85%	29.86%	13.32%
Operating Margin	15.37%	18.27%	14.26%	5.35%
Profit Margin	12.35%	14.72%	9.47%	3.66%
Free Cash Flow Margin	-12.08%	-17.53%	-16.22%	-3.18%
EBITDA	91.44	52.61	36.09	22.75
EBITDA Margin	15.69%	19.11%	15.53%	5.63%
D&A For EBITDA	1.89	2.32	2.95	1.12
EBIT	89.55	50.29	33.14	21.64
EBIT Margin	15.37%	18.27%	14.26%	5.35%
Effective Tax Rate	17.19%	-	25.65%	30.82%
Revenue as Reported	585.4	276.57	232.65	404.46
Advertising Expenses	-	0.03	0.22	0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.